Table 4: Characteristics of 142 HIV patients.

CategoryFrequency/median

Gender
 Male96
 Female46
Age35
Yang-Deficient Constitution score25
HIV disease staging
 A57
 B16
 C69
Mortality5
CD4 count
 Baseline 113
 3 months after HAART202
 6 months after HAART206
 9 months after HAART229
 12 months after HAART269
CD8 count
 Baseline678.5
 3 months after HAART837
 6 months after HAART836
 9 months after HAART861
 12 months after HAART934
Highly active antiretroviral therapy
 3TC142
 AZT45
 D4T95
 EFV71
 NVP62
 KALETRA7
 TDF1
Infection status before starting HAART
 Presence of infection before starting HAART50
 Hepatitis B16
 Hepatitis C19
 Pulmonary tuberculosis30
 Extrapulmonary tuberculosis12
 Pneumonia42
 Superficial fungal infections37
 Visceral fungal infections31
 Intestinal infections10
 Encephalitis and meningitis5
 Sexually transmitted disease2
Newly acquired infection after HAART
 Presence of newly acquired infection after HAART29
 Pulmonary tuberculosis1
 Extrapulmonary tuberculosis6
 Pneumonia7
 Superficial fungal infections2
 Visceral fungal infections6
 Intestinal infections8
 Encephalitis and meningitis2
 Other infections5
Immune reconstitution inflammatory syndrome (IRIS)9
Adverse events
 Fatigue18
 Allergy50
 Alopecia1
 Gastrointestinal reaction 44
 Mouth epithelium ulcer and pharyngitis7
 Cerebral symptom 26
 Arthralgia3
 Diabetes1
 Hematologic toxicity48
 Hepatotoxicity49
 Abnormal lipid metabolism26
 Pancreatitis0
 Nephrotoxicity11
 Sensory nerve dysfunction17
 Hyperlactacidemia18
Total number of side effects24
Number of days an infection occurred after HAART initiation 80